Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
ODDITY TECH 0CDI.PA-O 0META 11.03MNT.TO 0.69COPX 1.79U.U.TO 0.5SII.TO 2.94IPCO.TO -0.43
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.57
+0.60 (2.15%)
as of Aug 25, 2026, 8:00:00 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) has faced challenges following its prominent role during the Covid-19 pandemic, with many experts pointing out the looming patent cliffs and the need for new blockbuster drugs to sustain growth. The company is heavily reliant on its dividends, offering yields between 6% to 8%, which many investors find attractive in a low growth environment. While some view it as a value play due to its low price-to-earnings ratio, others express concerns that it may be a value trap due to uncertain growth prospects. The overall sentiment reflects a cautious approach, favoring the dividend payout amidst worries about drug pipeline sustainability and the impact of recent acquisitions on its future performance.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
BUY

Pfizer Inc(PFE)

Feb 01, 2012
Pharma: The trend is really looking quite good. Hasn’t looked at Pfizer in a while. There was a time when it was 0% return for 10 years. Now, it is in the right sector and it is moving.
Photo of Mike S. Newton, CIM FCSIMike S. Newton, CIM FCSIUnlock Rating
$21.31

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Jan 26, 2012
One of the defensive stocks that did very, very well last year. Starting to see it roll over a little bit. Technically speaking it still looks pretty sound with the 200 day moving upwards and the 50 day moving across the 200 day very recently. Dividend is about 4%. Doesn't look at this as a tremendous growing company but is in the mid to high single digit range.
Photo of Stan WongStan Wong
No
Unlock Rating
$21.63

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 09, 2012
(Market Call Minute.) Good dividend yield. Company is buying back a lot of stocks. Well-run in a very tough business.
Photo of John O'Connell, CFAJohn O'Connell, CFAUnlock Rating
$21.82

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 04, 2012
His model price is $26.88, which is a 22% positive differential. Yielding 4%. This happens to be one that has valuation and yield together, which is great. His target would be about $26.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$21.77

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 23, 2011
Pharmaceutical space is tough. Lipitor is a drug that is going off-patent which will reduce their income.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$18.45

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 21, 2011
The 3 sectors hated sectors in the US are financials, healthcare and technology. They have done a lot of smart things recently. They increased the dividend and announced a share buyback. Valuation is quite cheap and he is looking at this one.
Photo of Barry SchwartzBarry Schwartz
No
Unlock Rating
$18.96

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Nov 15, 2011
A good space. Defensive name. Prefers JNJ. Seeing higher lows this year. Could come down to a higher low. Ranked 5th on his list. Would hold it.
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSIUnlock Rating
$19.87

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Oct 24, 2011
The whole pharma business is challenged. PFE is predicting lower revenues next year. Management is talking about breaking up the company. With Lipitor patent expiring, he would just sell it.
Photo of Gordon ReidGordon ReidUnlock Rating
$19.36

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 12, 2011
Suffering from loosing their patent on lipitor. Will be a pullback on earnings. Trying to reassess their businesses and potentially spinning some off. Not a big fan of large cap Pharma. Prefers diversified health care companies like Abbot.
Photo of Christine PooleChristine PooleUnlock Rating
$18.82

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 23, 2011
Debt rating cut but it doesn’t matter to him. They all have the patent cliff. He likes that they bought Wyeth who have a lot of drugs on patent. People say PFE is too big to make a difference if a new drug comes along so they are shrinking the company. Big, safe dividends.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$17.45

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 28, 2011
Lipitor is coming off patent and accounts for a boat 20% of their revenues. Sales are expected to drop about 5% next year.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$19.36

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Jul 22, 2011
Largest drug company in the world. Good pipeline, but they have been paring it down to focus on new drugs. Prefers Teva.
Photo of Richard FoglerRichard Fogler
No
Unlock Rating
$20.07

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Jun 16, 2011
This would be his 2nd choice after Eli Lilly (LLY-N). Facing the issue of a patent cliff where drugs are coming off patent. Has about 4 drugs expecting to move into phase 3 trials. Very attractive multiple. Good dividend yield.
Photo of Mohsin BashirMohsin BashirUnlock Rating
$20.24

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

May 12, 2011
Largest global pharma. Likes it. Whole pharma sector has been suffering from a lack of new block buster drugs. This one is facing the expiration of the patent on their Lipitor drug but this is already reflected in the stock price. Have some very promising drugs in phase 2 and 3 clinical trials. Stock is not expensive and has a 4% yield.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$20.89

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 27, 2011
Has done well lately on the potential of it breaking up and selling off the pieces. The difficulty in the whole pharma sector is that it is tough to grow.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$20.63

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 421 to 435 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

ATD.TO -0.8$85.19
1523.HK 0$
CSU.TO -20.01$3078.66
NVO 1.74$48.66
PAYC 2.08$231.7
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

ODDITY T… 0$
CDI.PA-O 0$
META 11.03$570.05
MNT.TO 0.69$69.95
COPX 1.79$96.32

Popular Articles

Latest Sell Signals

ORCL 2.31$144.76
GAW-LSE 0$
BB.TO 0.17$10.79
SHOP.TO 5.21$212.84
IBM 3.15$234.19

Most Recent Experts

Jason Del Vicario

Jason Del Vicario

HollisWealth

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like